Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, ...

The global BPH treatment market is expected to grow from USD 33,031.10 million in 2024 to USD 47,045.80 million by 2034, at a ...

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

A report reveals that Defense Secretary Lloyd Austin's secret 2024 hospitalization for prostate cancer surgery sparked criticism due to lack of communication within the government. Austin took ...

ROACH: I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One blood test showed a PSA level of 13 ng/mL, and a second was 17 ng/mL ...

Starting Jan. 1, 2025, millions of Americans who get their prescription drugs through Medicare could get a major financial break when a $2,000 out-of-pocket spending cap on medications goes into ...

With no current drug treatment to assist people in getting off meth, the study’s findings are promising. For those with an amphetamine-type stimulant use disorder (ATSUD), their drug misuse ...

MORGANTOWN – Mon Health Medical Center is once again on the leading edge of surgery – this time with a new technology to treat enlarged prostate ... provide advanced treatment options to ...

A recent survey reveals a significant decline in teen drug and alcohol use since 2017, reaching its lowest point in 2024. Researchers attribute this drop to pandemic lockdowns disrupting social ...

The Food and Drug Administration (FDA) has approved Gemtesa ® (vibegron) for the treatment of overactive ... on pharmacological therapy for benign prostatic hyperplasia (BPH).

New trials, including Focal One robotic HIFU and ProVee System, are exploring novel approaches to BPH treatment, expanding therapeutic options. Real-world data support the safety and efficacy of ...